Xeris Pharmaceuticals Inc (XERS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 91,598 | 59,285 | 58,440 | 71,621 | 59,232 |
| Marketable Securities | N/A | N/A | N/A | N/A | 10,170 |
| Receivables | 53,751 | 53,048 | 46,330 | 40,415 | 41,138 |
| Inventories | 67,462 | 67,282 | 52,690 | 48,175 | 45,119 |
| TOTAL | $224,017 | $185,578 | $163,494 | $167,662 | $162,799 |
| Non-Current Assets | |||||
| PPE Net | 4,946 | 5,284 | 5,260 | 5,562 | 5,613 |
| Intangibles | 113,648 | 116,359 | 119,070 | 121,780 | 124,491 |
| Other Non-Current Assets | 27,580 | 27,465 | 27,629 | 28,056 | 28,201 |
| TOTAL | $146,174 | $149,108 | $151,959 | $155,398 | $158,305 |
| Total Assets | $370,191 | $334,686 | $315,453 | $323,060 | $321,104 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 0 | 0 | 11,959 | 15,102 | 15,057 |
| Accounts payable and accrued liabilities | 6,527 | 9,462 | 6,352 | 2,290 | 7,451 |
| Accrued Expenses | 70,480 | 52,951 | 50,438 | 48,166 | 38,242 |
| Other current liabilities | 2,649 | 1,633 | 156 | 1,089 | 678 |
| TOTAL | $116,200 | $95,171 | $95,072 | $100,443 | $91,013 |
| Non-Current Liabilities | |||||
| Long Term Debt | 219,469 | 218,626 | 217,805 | 217,006 | 216,227 |
| Other Non-Current Liabilities | 35,383 | 40,193 | 37,704 | 35,226 | 42,187 |
| TOTAL | $254,852 | $258,819 | $255,509 | $252,232 | $258,414 |
| Total Liabilities | $371,052 | $353,990 | $350,581 | $352,675 | $349,427 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 165,924 | 161,480 | 160,155 | 153,940 | 149,082 |
| Common Shares | 17 | 16 | 16 | 15 | 15 |
| Retained earnings | -682,388 | -683,009 | -681,081 | -671,861 | -666,748 |
| Other shareholders' equity | -25 | -24 | -25 | -25 | -16 |
| TOTAL | $-861 | $-19,304 | $-35,128 | $-29,615 | $-28,323 |
| Total Liabilities And Equity | $370,191 | $334,686 | $315,453 | $323,060 | $321,104 |